Linda F. M. Stynenbosch

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

Marij J.P. Welters, Gemma G. Kenter, Peggy J. de Vos van Steenwijk et al. · Proceedings of the National Academy of Sciences · 2010 · 238 citations · Full text

Medicine, Immunology, Oncology +17

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Edith M.G. van Esch et al. · Journal of Translational Medicine · 2013 · 187 citations · Full text

Medicine, Immunology, Oncology +17

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Renee Vermeij et al. · Clinical Cancer Research · 2016 · 165 citations

Medicine, Immunology, Oncology +17

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

Peggy J. de Vos van Steenwijk, Mariëtte I.E. van Poelgeest, Tamara H. Ramwadhdoebé et al. · Cancer Immunology Immunotherapy · 2013 · 68 citations · Full text

Medicine, Immunology, Oncology +16

Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

Eliane C.M. Zeestraten, Frank M. Speetjens, Marij J.P. Welters et al. · International Journal of Cancer · 2012 · 61 citations · Full text

Medicine, Immunology, Oncology +17